Sinovac stock: buy or sell?

SVA stock price: $6.47 -0.31% At close on February 22nd, 2019

Updated on:
February 22nd, 2019


Sinovac ended on February at $6.47 and stayed stable a lame -0.31%.

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China.

Should I buy Sinovac stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with Sinovac stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Sinovac Biotech stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for SVA stock for the last month.

Sinovac stock analysis

Daily outlook

Sinovac shares stayed stable -0.31% to $6.47 on February.

Sinovac closed on February at $6.47 and stayed steady a lame -0.31%.

SVA stock chart (daily)

Weekly outlook

Sinovac Biotech closed this week at $6.47 and gained a tiny 0.62%. Early January SVA plummed a dreadful -5.71% in just one week.

Weekly chart tells us that price is in a simple uptrend, tested $6.30 level and now climbing back aiming its last top at $7.10.

SVA stock chart (weekly)

Sinovac stock price history

Sinovac stock went public on November 3rd, 2003 with a price of $0.821. Since then, SVA stock grew a 689.00%, with an average of 45.90% per year. If you had invested $1,000 in Sinovac stock in 2003, it would worth $6,890.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Sinovac stock historical price chart

SVA stock reached 52-week highs at $8.75, and all-time highs 2009-09-01 with a price of 12.5.

Sinovac stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price target for Sinovac stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since last November, when Sinovac presented its last earnings report, it collapsed a scary -16.19%. Unfortunately, reported EPS is not yet available in our database.
SVA earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2016, last anual revenues report draw an outstanding gain of 140.71% to $174.35 M dollars. When comparing 2017 vs 2016, aligned with this, profit margin (that is, the net income divided by revenues) boosted a 15.63% to 14.80%.

SVA annual Sales and Income evolution
2012$49 M-$-14.85 M-30.2%-
2013$73 M47.34%$7.44 M10.3%-150.10%
2014$63 M-12.99%$-0.85 M-1.3%-111.44%
2015$67 M6.84%$-1.07 M-1.6%26.20%
2016$72 M7.44%$-0.60 M-0.8%-44.51%
2017$174 M140.71%$26 M14.8%-4,430.03%

Quarterly financial results

Reported quarter earnings marked million with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was nan%. When comparing revenues to same quarter last year, Sinovac sales marked a tight movement and remained steady a nan%.
SVA quarterly Sales and Income evolution
2016-Q3$28.74 M-$3.21 M11.2%-
2016-Q4$31.37 M9.15%$4.45 M14.2%38.81%

Sinovac ownership

When you are planning to buy a stock, it's worth to have a look its ownership structure.

Sinovac shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.59% of all shares.

In case of Sinovac stock, 2.38% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SVA stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Sinovac Biotech:

Market cap$640.0 M$48.2 B$435.2 M$198.8 B$197.7 B
Total shares98.9 M1,270.0 M64.0 M4,920.0 M2,580.0 M
Float shares41.9 M2,530.0 M58.7 M2,430.0 M2,580.0 M
  - Institutional holdings (%)2.4%19.4%85.1%11.0%78.3%
  - Insider holdings (%)3.6%0.0%1.2%0.0%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Sinovac summary

Friday, February 22nd, 2019
Day range$6.25 - $6.58
Previous close$6.49
Session gain-0.31%
Average true range$0.17
50d mov avg$6.67
100d mov avg$7.07
200d mov avg$7.25
Daily pattern
Weekly pattern lb01a

Sinovac performance

To better understand Sinovac performance you must compare its gains with other related stocks in same sector or industry. We selected Astrazeneca, Dynavax Technologies, GlaxoSmithKline, Merck, NewLink Genetics, NanoViricides, Novavax, Novartis and SIGA Technologies as the bechmarking frame for Sinovac Biotech stock.
SVASinovac Biotech-10.14%2.54%-21.00%
DVAXDynavax Technolog...-38.52%-43.24%-62.84%
NLNKNewLink Genetics21.28%-11.40%-63.77%
SIGASIGA Technologies-24.13%1.16%-12.56%

Sinovac competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Sinovac. We selected 9 companies as Sinovac competitors as they are in the same industry or have similar market objectives.